PARP1 and cancer: In addition, BRCA1/2 somatic mutations have also been proposed in various cancers.[9–11] With the deepening of research, 4 PARP inhibitors olaparib, rucaparib, niraparib, and talazoparib have been approved by the Food AND Drug Administration (FDA) and the European Medicines Agency (EMA).[5] From 2014 to 2016, olaparib and rucaparib were approved to treat advanced ovarian cancer.